Immunotherapeutic role of Ag85B as an adjunct to antituberculous chemotherapy
2011

Immunotherapy with Ag85B for Tuberculosis Treatment

Sample size: 5 publication 10 minutes Evidence: moderate

Author Information

Author(s): Sheikh Javaid A, Khuller Gopal K, Verma Indu

Primary Institution: Postgraduate Institute of Medical Education and Research, Chandigarh, India

Hypothesis

Can Ag85B enhance the effectiveness of antituberculous chemotherapy in treating tuberculosis?

Conclusion

The combination of immunotherapy with Ag85B and chemotherapy shows promise in improving tuberculosis treatment outcomes.

Supporting Evidence

  • Ag85B significantly reduced bacterial numbers in the spleen and lung compared to controls.
  • The therapeutic effect of Ag85B was comparable to short-term chemotherapy.
  • Immunotherapy with Ag85B allowed for reduced dosages of antituberculous drugs.

Takeaway

This study found that using a special protein called Ag85B along with regular tuberculosis medicine can help fight the disease better.

Methodology

Mice infected with Mycobacterium tuberculosis were treated with chemotherapy or immunotherapy, and bacterial counts were measured in lungs and spleen.

Limitations

The study was conducted in a mouse model, which may not fully replicate human responses.

Participant Demographics

6-8 week old female Balb/c mice

Statistical Information

P-Value

p<0.001

Confidence Interval

95% CI

Statistical Significance

p<0.001

Digital Object Identifier (DOI)

10.1186/1476-8518-9-4

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication